News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
73–89
Matches
89
Sources here
10
Companies here
1
Search results Stored financial headlines

Active search

89 matching headlines

Ticker or company: BBIOMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Simply Wall Street Earnings Main company 🇺🇸 United States

Is FDA’s Encaleret NDA Acceptance Redefining the Investment Case For BridgeBio Pharma (BBIO)?

BridgeBio Pharma's encaleret New Drug Application for ADH1 has been accepted by the FDA, with a PDUFA target date of May 8, 2027. This potential first-in-indication therapy could transform the investment case for BridgeBio, placing it alongside other key 2026-2027 milestones. While this strengthens …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Monashee Investment Management LLC Reduces Holdings in BridgeBio Pharma, Inc. $BBIO

Monashee Investment Management LLC significantly reduced its stake in BridgeBio Pharma (NASDAQ:BBIO) by 32.9% in the first quarter, now owning 67,139 shares valued at $4.99 million. This adjustment makes BridgeBio its 12th largest holding. Despite Monashee's reduction and insider selling, Wall Street analysts generally …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Earnings Main company 🇺🇸 United States

BridgeBio (BBIO) UBS Global Healthcare Conference 2025 Summary

This article summarizes BridgeBio's presentation at the UBS Global Healthcare Conference 2025. Key points include strong commercial performance for Attruby with rapid uptake and no immediate pricing pressure, and a positive outlook on market expansion for its products. The company also highlighted significant clinical …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Regulatory and legal Main company 🇺🇸 United States

FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug

The FDA has accepted BridgeBio's regulatory filing for encaleret, a drug targeting autosomal dominant hypocalcemia type 1 (ADH1), with a decision expected by May 8, 2027. This marks a significant step for BridgeBio, as encaleret could become the first FDA-approved treatment for ADH1 and …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Market update Main company 🇺🇸 United States

BBIO5355568 Bond Risk Profile

This page provides a risk profile for the BridgeBio Pharma, Inc. 2.25% 01-FEB-2029 BBIO5355568 bond. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help users evaluate the bond's reliability. The page also mentions access to …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GuruFocus Earnings Main company 🇺🇸 United States

BridgeBio Pharma (BBIO) Gains FDA Acceptance for Encaleret in Rare Hypoparathyroidism

BridgeBio Pharma (BBIO) has received FDA acceptance for its New Drug Application (NDA) for encaleret, a treatment for autosomal dominant hypocalcemia type 1, a rare form of hypoparathyroidism. The FDA has set a target action date of May 8, 2027, and will not hold …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GuruFocus Earnings Main company 🇺🇸 United States

BridgeBio (BBIO) Receives FDA Filing Acceptance for New Drug App

BridgeBio Pharma Inc (BBIO) announced that the FDA has accepted its new drug application (NDA) for encaleret, a treatment for autosomal dominant hypocalcemia type 1. The FDA has set a target action date of May 8, 2027, and does not plan to convene an …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quiver Quantitative Earnings Main company 🇺🇸 United States

BridgeBio Pharma Announces FDA Acceptance of NDA for Encaleret in ADH1, Sets PDUFA Date of May 8, 2027

BridgeBio Pharma announced that the FDA has accepted its New Drug Application for encaleret, a potential treatment for autosomal dominant hypocalcemia type 1 (ADH1), setting a PDUFA target action date of May 8, 2027. If approved, encaleret would be the first specific therapy for …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Seeking Alpha Market update Main company 🇺🇸 United States

BridgeBio granted FDA review for hypoparathyroidism therapy

BridgeBio Pharma announced that the U.S. FDA has accepted its New Drug Application for encaleret, a therapy for autosomal dominant hypocalcemia type 1, a rare form of hypoparathyroidism. The FDA's acceptance initiates the review process for this marketing application.

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Market update Main company 🇺🇸 United States

BBIO5355568 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the BBIO5355568 bond issued by BridgeBio Pharma, Inc. It details that the bond has a 2.25% coupon rate, with the next payment scheduled for August 3, 2026. The profile offers insights into the bond's interest payments and …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Simply Wall Street Earnings Main company 🇺🇸 United States

BridgeBio Pharma (BBIO) Faces A Valuation Test As Pipeline Optimism Builds

BridgeBio Pharma (BBIO) has seen significant share price growth due to investor optimism surrounding its late-stage pipeline. Its fair value is estimated at $102.71, suggesting it is currently undervalued, but its high P/S ratio indicates investors are already factoring in future growth. The article …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Market update Main company 🇺🇸 United States

US10806XAH5 Bond Risk Profile

This article provides a risk profile for the BridgeBio Pharma, Inc. 1.75% 01-MAR-2031 bond (US10806XAH5), traded on the Frankfurt Stock Exchange. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate the bond's reliability. …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quiver Quantitative Market update Main company 🇺🇸 United States

Lobbying Update: $280,000 of BRIDGEBIO PHARMA INC. lobbying was just disclosed

BRIDGEBIO PHARMA INC. (BBIO) disclosed $280,000 in lobbying expenditures for Q4 2025, focusing on issues like the "Give Kids a Chance Act of 2025," PBM Reform, and the "ORPHAN Cures Act." The article also details recent congressional stock trading activity by Representative Gilbert Ray …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Analyst action Main company 🇺🇸 United States

Citi Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $93

Citi has reiterated its Hold rating on BridgeBio Pharma (BBIO.US) and maintained its target price at $93. This indicates that Citi analysts believe the stock is currently fairly valued or that there are no strong catalysts for significant upward or downward movement in the …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Sharemaestro Market Watch Volume surge Main company 🇺🇸 United States

BridgeBio Pharma Inc (BBIO) climbs 28.6% over four weeks as volume doubles

The biotechnology stock’s latest weekly move came with heavier turnover, but the trend read remains inactive.

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Market update Main company 🇺🇸 United States

BridgeBio Pharma Company Profile & Introduction

This document is an introduction to the company BridgeBio Pharma. Further details about the company are expected to be provided within the content of this profile.

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Sharemaestro News Company research Main company 🇺🇸 United States

BridgeBio’s rebound gets 34.6M-share confirmation, but the weekly regime has not switched on

BBIO rose 11.3% in the latest week and now sits 19.3% above its weekly Trend Line, with participation twice its 13-week norm. The caution is that Sharemaestro’s Trend Signal remains inactive and the stock is trading at a large premium to co

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context